Design of Clinical Trials Evaluating Sedation in Critically Ill Adults Undergoing Mechanical Ventilation: Recommendations From Sedation Consortium on Endpoints and Procedures for Treatment, Education, and Research (SCEPTER) Recommendation III. by Ward, DS et al.
1684     www.ccmjournal.org October 2021 • Volume 49 • Number 10
DOI: 10.1097/CCM.0000000000005049
Copyright © 2021 The Author(s). 
Published by Wolters Kluwer Health, 
Inc. on behalf of the Society of Critical 
Care Medicine and Wolters Kluwer 
Health, Inc. This is an open-access ar-
ticle distributed under the terms of the 
Creative Commons Attribution-Non 
Commercial-No Derivatives License 4.0 
(CCBY-NC-ND), where it is permissible 
to download and share the work provided 
it is properly cited. The work cannot be 
changed in any way or used commercially 
without permission from the journal.
OBJECTIVES: Clinical trials evaluating the safety and effectiveness of 
sedative medication use in critically ill adults undergoing mechanical ven-
tilation differ considerably in their methodological approach. This heteroge-
neity impedes the ability to compare results across studies. The Sedation 
Consortium on Endpoints and Procedures for Treatment, Education, and 
Research Recommendations convened a meeting of multidisciplinary experts 
to develop recommendations for key methodologic elements of sedation tri-
als in the ICU to help guide academic and industry clinical investigators.
DESIGN: A 2-day in-person meeting was held in Washington, DC, on 
March 28–29, 2019, followed by a three-round, online modified Delphi 
consensus process.
PARTICIPANTS: Thirty-six participants from academia, industry, and the 
Food and Drug Administration with expertise in relevant content areas, in-
cluding two former ICU patients attended the in-person meeting, and the 
majority completed an online follow-up survey and participated in the mod-
ified Delphi process.
MEASUREMENTS AND MAIN RESULTS: The final recommendations 
were iteratively refined based on the survey results, participants’ reactions 
to those results, summaries written by panel moderators, and a review of 
the meeting transcripts made from audio recordings. Fifteen recommenda-
tions were developed for study design and conduct, subject enrollment, 
outcomes, and measurement instruments. Consensus recommendations 
included obtaining input from ICU survivors and/or their families, ensuring 
adequate training for personnel using validated instruments for assess-
ments of sedation, pain, and delirium in the ICU environment, and the need 
for methodological standardization.
CONCLUSIONS: These recommendations are intended to assist 
researchers in the design, conduct, selection of endpoints, and reporting 
of clinical trials involving sedative medications and/or sedation protocols 
for adult ICU patients who require mechanical ventilation. These recom-
mendations should be viewed as a starting point to improve clinical trials 
and help reduce methodological heterogeneity in future clinical trials.
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Clinical practice guidelines for managing me-chanically ventilated adults in the ICU ac-knowledge the lack of high-quality evidence 
on which to base recommendations for sedation and 
analgesia (1, 2). High-quality evidence is sparse be-
cause numerous barriers make clinical research in 
this area complex (3). An absence of standardized 
approaches to study design and methods and a lack 
of consensus on the most important clinical outcomes 
and measures are notable barriers. For example, a 
sampling of clinical trials on ICU sedation from the 
“ClinicalTrials.gov” website and several recently pub-
lished trials (4–8) revealed substantial heterogeneity 
in their inclusion and exclusion criteria, primary and 
secondary efficacy outcomes, safety outcomes, meas-
urement instruments, and timing of outcome meas-
ures relative to the sedative intervention and ICU 
admission. Unfortunately, such heterogeneity hinders 
meaningful comparisons across trials and prevents the 
use of meta-analysis to synthesize evidence and pro-
vide recommendations regarding how to optimally 
provide sedation for mechanically ventilated adults in 
the ICU (8).
To address these gaps, the Sedation Consortium on 
Endpoints and Procedures for Treatment, Education 
and Research (SCEPTER) convened a meeting that 
focused on the design and conduct of clinical tri-
als for sedation management in critically ill adults 
who require mechanical ventilation (SCEPTER 
III). SCEPTER is part of the Analgesic, Anesthetic, 
Addiction Clinical Trial Translations, Innovations, 
Opportunities, and Networks (ACTTION) pub-
lic-private partnership with the Food and Drug 
Administration (FDA) (9). Previous recommenda-
tions regarding the design of clinical trials for pro-
cedural sedation have been developed by SCEPTER 
(10, 11). Briefly, ACTTION was conceived as part of 
the FDA’s Critical Path Initiative (12), with a mission 
“… to identify, prioritize, sponsor, coordinate, and 
promote innovative activities—with a special interest 
in optimizing clinical trials—that will expedite the 
discovery and development of improved analgesic, 
anesthetic, addiction, and peripheral neuropathy 
treatments for the benefit of the public health.”
The purpose of the SCEPTER III meeting was 
to develop pragmatic, evidence-based guidance 
to clinical investigators who are designing, con-
ducting, and reporting clinical trials evaluating 
sedation in mechanically ventilated adults in the ICU. 
Recommendations for key elements of study design, 
conduct, and reporting of sedation-related clinical 
trials in the ICU are offered to help facilitate com-
parison of studies of new agents, combinations, or 
protocols.
METHODS
A 2-day, in-person meeting was held in Washington, 
DC, on March 28–29, 2019. This meeting was followed 
by a modified Delphi consensus process (conducted 
online from February through June 2020) that focused 
on discussion points from the in-person meeting. This 
article reports on results of both the meeting and the 
modified Delphi consensus process.
Meeting
The meeting agenda and participant list were developed 
by a seven-member ACTTION/SCEPTER III steering 
committee, supplemental data 1 (http://links.lww.com/
CCM/G350) and supplemental data 2 (http://links.lww.
com/CCM/G351) present the steering committee mem-
bership and the meeting agenda, respectively. Participants 
were an international, interprofessional group of experts 
who had either attended prior SCEPTER meetings, pub-
lished research involving sedation in adult ICUs, and/or 
were experts in clinical trial design, short- and long-term 
ICU patient outcomes, pharmacology, and/or statistics. 
Attendees included clinical, academic, patient, FDA, and 
industry representatives.
Prior to the meeting, participants were asked to re-
view the Society of Critical Care Medicine’s (SCCM) 
2018 Pain, Agitation/Sedation, Delirium, Immobility, 
Sleep Disruption guidelines (1), two prior SCEPTER 
meeting publications (10, 11), and the SCEPTER III 
agenda. Thirty-six participants from academia, in-
dustry, and the FDA with expertise in relevant content 
areas and two former ICU patients attended the in-
person meeting which included formal presentations, 
panel-led discussions, and informal discussion time. 
Particularly noteworthy was the session devoted to the 
patient and family perspective. The presentation from 
an ICU survivor was followed by a panel discussion led 
by another ICU survivor (supplemental data 2, (http://
links.lww.com/CCM/G351). Both ICU survivors are 
anesthesiologists who had explicit memory of their time 
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in the ICU, providing a unique perspective. The meeting 
was audio-recorded and professionally transcribed (13).
Postmeeting Modified Delphi Consensus 
Process
Following the in-person meeting, in July 2019, an on-
line survey Supplemental Table 1 (http://links.lww.
com/CCM/G352) was sent to all participants to assess 
their perspectives on key points discussed at the meet-
ing. Survey results, participants’ reactions to those 
results, written summaries of the meeting panel dis-
cussions provided by the panel moderators, and a re-
view of the meeting transcripts formed the basis for 
generating questions for the modified Delphi con-
sensus process. These questions were written by two 
authors (D.W., D.E.), neither of whom participated 
in the survey. The questions were pilot tested and re-
fined based on feedback with several intensivists. 
This modified Delphi protocol was reviewed by the 
University of Rochester Research Study Review Board 
(Institutional Review Board) and determined to be ex-
empt (Study00003771). Web based software (Mesydel, 
Seraing, Belgium; https://mesydel.com/en) was used 
to conduct each round of the modified Delphi process.
Within the modified Delphi process, a nine-point 
Likert scale was used for most responses, anchors 
were “Not Important” (score: 1–3), “Important but 
Not Critical” (score: 4–6), and “Critical” (score: 7–9). 
A “No opinion” option was also provided (14). The 
remaining questions required selection of a specific 
time interval. As determined a priori, a recommenda-
tion was considered to have reached consensus when 
greater than or equal to 70% of respondents rated the 
recommendation as “Critical” (score ≥ 7) and less than 
or equal to 15% of respondents rated the recommen-
dation as “Not Important.” For questions with a time 
scale response, consensus was defined as greater than 
or equal to 70% of respondents agreeing on a specific 
response option. Recommendations reaching this def-
inition of consensus were not included in subsequent 
Delphi rounds. In the first and second Delphi rounds, 
participants could include comments, which were 
anonymously shared with all participants as part of the 
subsequent round. After three rounds, questions with 
greater than or equal to 70% of responses as “Important 
but Not Critical” or “Not Important” were also noted.
Final recommendations for this report, summarized 
in tabular form, were developed based on the meeting 
discussions, panel summaries, transcripts, and the 
modified Delphi consensus process, with iterative re-
finement of the draft recommendations by participants 
of the SCEPTER III meeting.
RESULTS
Table 1 outlines the recommendations for key ele-
ments of a clinical trial of a new sedative, combina-
tion of sedatives, or sedation strategy in critically ill 
adults who require mechanical ventilation and repre-
sents the combined results of the 2-day meeting and 
the subsequent three-round modified Delphi con-
sensus process. These recommendations aim to en-
hance the consistency and comparability of future 
sedation trials. Supplemental Table 2 (http://links.
lww.com/CCM/G353) reports results for each Delphi 
recommendation.
Key Recommendations—Study Development
Critically ill adults represent a heterogenous study 
population even in specialty-focused ICUs. Study el-
igibility criteria should be defined to select patients 
most likely to benefit from the proposed intervention 
while balancing potential limitations of a restricted pa-
tient population for trial enrollment as well as study 
generalizability. Whenever possible, measurement 
instruments should have evidence of validity and re-
liability in the proposed study population and setting 
and should be used in a manner consistent with such 
evidence. The lack of validated assessment tools for 
alcohol and opioid withdrawal in critically ill adults 
represents a particularly pertinent gap for sedation 
research.
The perspectives of survivors of critical illness and 
their family/caregivers should also be considered dur-
ing the clinical trial design to ensure a patient-centered 
focus. The impact of critical illness on the patient can-
not be separated from the impact on loved ones and 
family members. The perspectives of survivors and 
family/caregivers are unique and panels assisting with 
study development should include both.
Key Recommendations—Study Enrollment
Patients eligible for a sedation clinical trial should be 
enrolled as early as possible within the constraints of 
urgent clinical care, availability of research staff, and 
the need for informed consent. Although enrollment 
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TABLE 1. 
Key Elements in the Design and Conduct of Clinical Trials of Sedation in Adult  
Mechanically Ventilated ICU Patients
Study design
  The specific clinical trial design will depend on the goals of the study, with adaptive, pragmatic, and/or 
noninferiority designs as potential options.
  The number of study sites, type of ICUs eligible for the study, and patient eligibility criteria, along with the 
rationale for these choices, should be explicitly stated in the study protocol.
  A panel of survivors of critical illness and their caregivers should be consulted throughout the design of the 
clinical trial (15).
Study enrollment
 The specific indication(s) for use of sedation in an enrolled patient should be recorded (4).
  Patient enrollment should occur as soon as possible, and preferably no later than 24 hr after initiation of 
sedation.
  A validated ICU severity of illness score (e.g., Acute Physiology and Chronic Health Evaluation, Sequential 
Organ Failure Assessment, Simplified Acute Physiology Score) should be recorded, preferably at the 
time of ICU admission or study enrollment (16–18).
Study conduct
  All pain, sedation, and delirium assessments should be performed by personnel who are trained in use of 
the assessment instrument (19). Ideally, these measurements are done by research (rather than clinical) 
personnel. Quality assurance monitoring of the completeness, accuracy, consistency, and reproducibility 
of the measures, over the duration of the study is recommended.
  The use of “rescue” medications (e.g., for patient agitation and pain) should be standardized via the study 
protocol, recorded, and reported.
Outcomes and measurement instruments
  Achieving the target level of sedation may be a primary or secondary outcome or a protocol adherence 
measure.
  The sedation level should be assessed at least every 4 hr using a valid and reliable scale (e.g., Richmond 
Agitation and Sedation Scale [20] or Sedation-Agitation Scale [21]). The Ramsay Sedation Scale is not 
recommended (22).
  Pain should be measured prior to study initiation and at least every 4 hr thereafter using a valid and reliable 
scale (e.g., numeric rating scale in patients who can self-report pain and the Critical Care Pain  
Observation Tool (23) or Behavioral Pain Scale in those who cannot [24]).
  Consideration should be given to treating pain to a prespecified score prior to any sedation assessment or 
administration of a sedative.
  Delirium should be assessed at least every 12 hr using a valid and reliable scale (e.g., Confusion  
Assessment Method for the ICU or Intensive Care Delirium Screening Checklist [25–28]).
  ICU and hospital mortality, length of stay, mechanical ventilation duration, and mortality at 30 d  
(and possibly up to 180 d) should be measured and reported.
  If outcomes beyond hospital discharge will be assessed, a core outcome measurement set for acute  
respiratory failure survivors should be used (14).
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prior to, or within 24 hours of, sedation initiation is 
ideal, later enrollment may be consistent with the goals 
of a clinical trial in some circumstances. Management 
of both control and intervention groups should be 
consistent with accepted clinical practice for the use of 
sedation medications and a target sedation level (e.g., 
no sedation vs light sedation vs deep sedation). Since 
heterogeneity in the patient population is expected, 
recording a validated ICU severity of illness score at 
the time of ICU admission or patient enrollment is 
recommended.
Key Recommendations—Study Conduct
Many measures (e.g., of level of sedation) are based on 
scoring systems with a subjective component. Ideally, 
all such assessments are performed by trained study 
personnel. However, this goal may not always be fea-
sible on evenings, nights, and weekends. If measures 
obtained by clinical personnel are used for research 
purposes, personnel training and quality assurance 
monitoring of the completeness, accuracy, consistency, 
and reproducibility of such measures, over the dura-
tion of the study, are recommended.
Key Recommendations—Outcome Measures
Important outcomes include both those occurring 
during the ICU admission and after ICU and hospital 
discharge. During the ICU stay, measures of sedation, 
pain, and delirium should be evaluated using valid and 
reliable instruments for the ICU setting. This recom-
mendation does not limit use of additional novel scales 
or techniques (e.g., processed electroencephalogram) 
in the study so long as they do not compromise the 
use of validated measures. The times to clinically im-
portant outcomes (e.g., extubation, ICU and hospital 
discharge, etc.) should be reported.
Consideration should be given to evaluating patient-
centered outcomes after hospital discharge (e.g., post 
intensive care syndrome including mental health, cog-
nition, and functional mobility as well as chronic pain, 
quality of life, etc.), while recognizing that proven asso-
ciations between ICU sedation and these outcomes is 
evolving. An existing core outcome measurement set 
(COMS) (14), designed for research studies evaluat-
ing postdischarge outcomes of acute respiratory failure 
survivors, was presented at the meeting. This COMS 
is recommended for use by both a National Heart 
Lung and Blood Institute working group on clinical re-
search in adult pulmonary and critical care (29) and 
the American Thoracic Society/European Respiratory 
Society task force as part of postdischarge follow-up 
of acute respiratory failure survivors with coronavirus 
disease 2019 (COVID-19) (30). Instruments from 
this COMS project also have also been recommended 
for clinical outpatient use by a SCCM international 
consensus conference (31). After the SCEPTER III 
meeting, a separate set of recommendations for meas-
urement instruments for outpatient clinical use in crit-
ical illness survivors was published (32).
DISCUSSION
An international group of interprofessional experts 
met to develop recommendations for the design, con-
duct, and reporting of clinical trials evaluating seda-
tion in adults requiring mechanical ventilation. The 
goals of the meeting were to improve the quality and 
consistency of data generated, reduce methodolog-
ical heterogeneity, and provide practical guidance 
for these trials. Herein, we discuss three themes that 
merit further elaboration: 1) incorporating views of 
surviving patients and/or families, 2) data collection 
quality assurance, and 3) need for methodological 
standardization.
With the increased call for patient-centered focus in 
clinical research (31), trialists should formally incor-
porate the perspectives of patients and families/care-
givers and patient comfort into the design of clinical 
trials of ICU sedation. Since posttraumatic stress dis-
order, depression, and other mental illnesses occur in 
the caregivers as well as ICU survivors, it is important 
to include both of these groups in a panel that is in-
volved in all aspects of the clinical trial (33, 34). The 
involvement of patient and family advisors has been 
considered critical in designing trials that are patient 
centered and whose results change clinical care prac-
tice and social support may change outcomes (34). In 
the United Kingdom, it is not possible to obtain gov-
ernment funding without effective patient and public 
involvement in all stages of the project (36). The 
Patient-Centered Outcomes Research Institute (32, 
37), among other funding bodies, has noted both the 
difficulty and importance of creating community part-
nerships that reflect the diversity of the population to 
be studied and eventually treated based on trial results. 
To achieve improved health equity and reduced health 
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disparities, we must strengthen the capacity to create 
partnerships with individuals and families living in 
diverse and underserved communities; better involve 
them in their care; and engage them in the improve-
ment of care processes, interprofessional education, 
and research (38).
The acute and severe nature of illness commonly 
experienced by patients in an ICU generally pre-
cludes a priori discussion of research participation. 
Furthermore, delirium is commonly experienced by 
adults in the ICU and limits patient participation. 
During his recovery, one of the authors reflected on 
delusions experienced during prolonged critical illness 
(15) and developed a framing tool for the ICU teams 
caring for him. Gaining patient and family perspectives 
during the design of a clinical trial may offer valuable 
insights to optimally serve future patients. Specifically, 
careful consideration of the nature of ICU patients’ 
experiences may improve the ability of clinical trials to 
help answer patient-centered research questions, opti-
mize enrollment, and improve patient and family sat-
isfaction with trial participation. In particular, family 
members are pivotal to patient enrollment because 
they usually serve as the legally authorized representa-
tives for ICU patients who commonly lack capacity for 
informed consent. Also, patients and families are an 
essential part of community engagement exercises that 
are required for potentially obtaining exemption from 
informed consent (39).
Assessments of pain, sedation, delirium and quality 
of life, using valid and reliable instruments, can 
measure important trial outcomes when completed by 
personnel trained in use of these instruments (40–44). 
For data collection around the clock, reliance on clin-
ical, rather than research, personnel may aid with feasi-
bility of frequent measurements; however, this reliance 
on busy clinical personnel has the potential to intro-
duce error. Hence, appropriate training and quality 
assurance is recommended for all personnel who per-
form such assessments required for sedation trials.
Clinical trials often use a “usual care” control group 
are sometimes unblinded and may have outcome meas-
ures that are subjective or can be influenced by actions 
of the clinical team. Hence, it is important to have a 
clear definition of “usual care” at the study site hospi-
tals, including consideration of this issue as part of the 
study site selection process and standardization of the 
control group (e.g., management of pain, management 
of agitation, extubation protocols). Furthermore, de-
signing study eligibility criteria to minimize the time 
interval between the start of sedation and study en-
rollment can help reduce exposure to medications that 
may confound assessment of the study intervention on 
the outcomes.
Several limitations of this work merit comment. The 
specific recommendations may have been influenced 
by the expert panel membership. The meeting attend-
ees have collectively published extensively on sedation 
and related subjects but cannot exhaustively capture all 
potential viewpoints. In addition, dominant voices or 
opinions within the panel may introduce bias. However, 
the panel members were purposely selected to provide 
expertise in the field, along with a wide range of experi-
ence and opinions, and there was facilitation of robust, 
but respectful, discussion and debate during the 2-day 
in-person meeting. The in-person meeting was specifi-
cally designed to allow ample time for both formal dis-
cussion during panel-led questions as well as informal 
discussions during the group social gatherings.
Although the Delphi process spanned the early 
months of the COVID-19 pandemic, the panel mem-
bers did not feel the pandemic affected our recom-
mendations. Clinical trials for sedation should be 
consistent across COVID and non-COVID popula-
tions. The observation that COVID-19 patients may 
require increased depth of sedation does underscore 
our recommendation that a severity of illness score 
be recorded for all patients entered into the clinical 
trial (45–47).
Furthermore, recommendations were refined using 
a postmeeting survey to help identify topics that de-
served further exploration or clarification via an 
anonymous, three-round, online modified Delphi 
consensus process followed by iterative refinement and 
debate. For example, there was discussion during the 
meeting on the problems of defining deep, moderate, 
and light sedation, which was deemphasized after the 
meeting in favor of recommendations concerning the 
sedation measurement instruments and frequency of 
evaluation.
In addition, these recommendations may not be 
suitable for all ICU trials, and adaptation of these rec-
ommendations may be appropriate for unique aspects 
of trial objectives and design. Furthermore, our focus 
was on pragmatic recommendations with the poten-
tial to reduce heterogeneity in clinical trial design, 
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conduct, and reporting. However, we realize some ICU 
sedation trials will want to incorporate novel features 
not considered in these recommendations that may 
still help advance the field.
CONCLUSIONS
An international group of interprofessional multidis-
ciplinary experts met, discussed, and agreed upon 15 
recommendations to assist with the design, conduct, 
and reporting of clinical trials of sedation of mechan-
ically ventilated adults in the ICU. We view these 
recommendations as the beginning of further devel-
opments and processes, with the goals of improving 
and reducing heterogeneity in research methods used 
in clinical trials and facilitating comparisons of studies 
of new sedation agents, combinations, or protocols.
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